An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients.

Trial Profile

An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Afuresertib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 10 Oct 2017 to 27 Dec 2017.
    • 15 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2016 Planned number of patients changed from 24 to 18.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top